PRTC
PureTech Health plc
Biotechnology
Market Cap$41M
5Y Perf.-57.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRTC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-18.4%
PRTC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRTC | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $41M | $1712.35T |
| Revenue (TTM) | $9M | $0.00 |
| Net Income (TTM) | $-56M | $-168M |
| Gross Margin | -196.2% | — |
| Operating Margin | -26.2% | — |
| Total Debt | $20M | $22M |
| Cash & Equiv. | $254M | $194M |
PRTC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRTC
DBVT
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| PureTech Health plc (PRTC) | 100 | 42.5 | -57.5% |
| DBV Technologies S.… (DBVT) | 100 | 81.6 | -18.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRTC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRTC leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PRTC
PureTech Health plc
The Income Pick
PRTC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.51
- Rev growth -3.5%, EPS growth -24.0%, 3Y rev CAGR 30.6%
- -55.9% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs PRTC's -6.2%
- +110.4% vs PRTC's -2.6%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRTC | -3.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs PRTC's -6.2% |
| Stability / Safety | PRTC | Beta 0.51 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs PRTC's -2.6% |
| Efficiency (ROA) | PRTC | -9.9% ROA vs DBVT's -89.0% |
PRTC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRTCLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
PRTCPureTech Health plc
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRTC8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
PRTC2/2
Analyst OutlookRatings, price targets, and dividends
PRTC1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRTC and DBVT operate at a comparable scale, with $9M and $0 in trailing revenue.
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $9M | $0 |
| EBITDAEarnings before interest/tax | -$228M | -$112M |
| Net IncomeAfter-tax profit | -$56M | -$168M |
| Free Cash FlowCash after capex | -$219M | -$151M |
| Gross MarginGross profit ÷ Revenue | -196.2% | — |
| Operating MarginEBIT ÷ Revenue | -26.2% | — |
| Net MarginNet income ÷ Revenue | -6.2% | — |
| FCF MarginFCF ÷ Revenue | -24.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -30.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -8.7% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PRTC and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $41M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | -$193M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.37x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.79x | — |
| Price / BookPrice ÷ Book value/share | 0.13x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PRTC and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRTC leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
PRTC delivers a -16.1% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-130 for DBVT. PRTC carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), PRTC scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -16.1% | -130.2% |
| ROA (TTM)Return on assets | -9.9% | -89.0% |
| ROICReturn on invested capital | -66.9% | — |
| ROCEReturn on capital employed | -18.8% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.13x |
| Net DebtTotal debt minus cash | -$234M | -$172M |
| Cash & Equiv.Liquid assets | $254M | $194M |
| Total DebtShort + long-term debt | $20M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -1.16x | -189.82x |
PRTC leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $2,988 for PRTC. Over the past 12 months, DBVT leads with a +110.4% total return vs PRTC's -2.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs PRTC's -16.3% — a key indicator of consistent wealth creation.
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +2.0% | +4.9% |
| 1-Year ReturnPast 12 months | -2.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | -41.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | -70.1% | -69.1% |
| 10-Year ReturnCumulative with dividends | -55.9% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +6.2% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PRTC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRTC is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRTC currently trades 85.2% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 1.26x |
| 52-Week HighHighest price in past year | $19.92 | $26.18 |
| 52-Week LowLowest price in past year | $14.50 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +85.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 48.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 8K | 252K |
PRTC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
PRTC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates PRTC as "Buy" and DBVT as "Buy". Consensus price targets imply 235.9% upside for PRTC (target: $57) vs 131.8% for DBVT (target: $46).
| Metric | PRTCPureTech Health p… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $57.00 | $46.33 |
| # AnalystsCovering analysts | 2 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.0% | 0.0% |
PRTC leads this category, winning 1 of 1 comparable metric.
Key Takeaway
PRTC leads in 3 of 6 categories (Profitability & Efficiency, Risk & Volatility). DBVT leads in 2 (Income & Cash Flow, Total Returns). 1 tied.
Best OverallPureTech Health plc (PRTC)Leads 3 of 6 categories
Loading custom metrics...
PRTC vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRTC or DBVT a better buy right now?
Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRTC or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -70. 1% for PureTech Health plc (PRTC). Over 10 years, the gap is even starker: PRTC returned -55. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRTC or DBVT?
By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.
51β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 147% more volatile than PRTC relative to the S&P 500. On balance sheet safety, PureTech Health plc (PRTC) carries a lower debt/equity ratio of 6% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — PRTC or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -24. 0% for PureTech Health plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PRTC or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -23. 6% for PureTech Health plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -21. 1% for PRTC. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PRTC or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRTC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, PureTech Health plc (PRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51)). Both have compounded well over 10 years (PRTC: -55. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRTC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.